Stockscreener 앱 받기
8.69
0.81%
0.07
시간 외 거래:
8.69
전일 마감가:
$8.62
열려 있는:
$8.65
하루 거래량:
542.34K
Relative Volume:
0.60
시가총액:
$448.55M
수익:
$170.44M
순이익/손실:
$-193.88M
주가수익비율:
-2.3148
EPS:
-3.7541
순현금흐름:
$-126.38M
1주 성능:
-4.61%
1개월 성능:
+11.98%
6개월 성능:
-33.97%
1년 성능:
-4.82%
1일 변동 폭
$8.60
$8.84
1주일 범위
$8.44
$9.55
52주 변동 폭
$6.89
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.69 | 444.94M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
Diabetic Retinopathy Pipeline Set for Transformational Breakthroughs by 2026 with 55+ Therapies expanding Clinical Innovation from Kodiak Sciences, Regenxbio, Adverum Biotechnologies | DelveInsight - Barchart.com
Diabetic Retinopathy Pipeline Set for Transformational - openPR.com
Regenxbio files $300M mixed shelf offering - MSN
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Regenxbio's DB-OTO Gene Therapy Approved for Genetic Hearing Los - GuruFocus
Sarepta Loses Bid to Rehear Regenxbio DNA Patent Case Decision - Bloomberg Law News
(RGNX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RGNX (REGENXBIO Inc.) reports wider than expected Q4 2025 loss while shares climb on positive investor sentiment.Market Hype Signals - Xã Thanh Hà
Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid - Law360
REGENXBIO credits administrative team for ongoing operational success - Traders Union
REGENXBIO (NASDAQ:RGNX) Shares Pass Below 200-Day Moving AverageShould You Sell? - MarketBeat
REGENXBIO prioritizes patient access by strengthening commercial leadership - Traders Union
Lifshitz Law Firm Investigating PayPal, Enphase Energy, and REGENXBIO - National Today
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of REGENXBIO Inc. to Contact the Firm Today! - ACCESS Newswire
RGNX DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts REGENXBIO Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
REGENXBIO Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
[ARS] REGENXBIO Inc. SEC Filing - Stock Titan
REGENXBIO (RGNX) 2026 proxy details director votes, auditor, and stock option exchanges - Stock Titan
RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REG - GuruFocus
User - The Chronicle-Journal
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APE - GlobeNewswire Inc.
REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Eastern Progress
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - The Joplin Globe
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026 - 巴士的報
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit — The Gross Law Firm - Morningstar
REGENXBIO DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class ActionRGNX - ACCESS Newswire
Levi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor Harm - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Rosen Law Firm Encourages REGENXBIO Investors to Secure Counsel Before Deadline - National Today
REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with ... - Bluefield Daily Telegraph
REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, - GlobeNewswire
How (RGNX) Movements Inform Risk Allocation Models - Stock Traders Daily
REGENXBIO DEADLINE: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class ActionRGNX - ACCESS Newswire
REGENXBIO DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class ActionRGNX - TMX Newsfile
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of REGENXBIO Inc. to Contact the Firm Today! - ACCESS Newswire
Portfolio Shifts: How is REGENXBIO Inc managing supply chain issues2026 Sentiment & High Conviction Investment Ideas - baoquankhu1.vn
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO ... - Bluefield Daily Telegraph
RGNX Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - ChartMill
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRGNX - wahanariau.com
Press releases provided by CNW - Techaeris
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - GuruFocus
Institution Moves: Is REGENXBIO Inc stock showing strong momentumOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming DeadlinesRGNX - PR Newswire
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of REGENXBIO Inc. to Contact the Firm Today! - ACCESS Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
RGNX Stockholders Have Opportunity to Lead REGENXBIO Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX - FinancialContent
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.00%
자본화:
|
볼륨(24시간):